Equillium Announces Three Abstracts Accepted for Presentation at the 104th AAI Annual Meeting

emailcarey
Apr 27, 2021
1 min read

Updated: May 12, 2021

Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients

https://ir.equilliumbio.com/news-releases/news-release-details/equillium-announces-three-abstracts-accepted-presentation-104th

Recent Posts

See All

Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results

Interim results of a Phase 1b trial of cirmtuz umab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast...

Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

- First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO®...

MatriSys Bioscience Names Joyce Rico as Chief Medical Officer

MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the hiring of Joyce...

MESA VERDE

VENTURE PARNERS

Equillium Announces Three Abstracts Accepted for Presentation at the 104th AAI Annual Meeting

Recent Posts

Comments